What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts

Supplemental Digital Content is available in the text.

Detalles Bibliográficos
Autores principales: Bommier, Côme, Lambert, Jérôme, Nowakowski, Grzegorz, Zucca, Emanuele, Thieblemont, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806367/
https://www.ncbi.nlm.nih.gov/pubmed/35141471
http://dx.doi.org/10.1097/HS9.0000000000000680
_version_ 1784643426630762496
author Bommier, Côme
Lambert, Jérôme
Nowakowski, Grzegorz
Zucca, Emanuele
Thieblemont, Catherine
author_facet Bommier, Côme
Lambert, Jérôme
Nowakowski, Grzegorz
Zucca, Emanuele
Thieblemont, Catherine
author_sort Bommier, Côme
collection PubMed
description Supplemental Digital Content is available in the text.
format Online
Article
Text
id pubmed-8806367
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-88063672022-02-08 What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts Bommier, Côme Lambert, Jérôme Nowakowski, Grzegorz Zucca, Emanuele Thieblemont, Catherine Hemasphere Letter Supplemental Digital Content is available in the text. Lippincott Williams & Wilkins 2022-01-31 /pmc/articles/PMC8806367/ /pubmed/35141471 http://dx.doi.org/10.1097/HS9.0000000000000680 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Letter
Bommier, Côme
Lambert, Jérôme
Nowakowski, Grzegorz
Zucca, Emanuele
Thieblemont, Catherine
What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
title What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
title_full What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
title_fullStr What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
title_full_unstemmed What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
title_short What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts
title_sort what prognostic markers should be evaluated in marginal zone lymphoma? a survey among leading international experts
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806367/
https://www.ncbi.nlm.nih.gov/pubmed/35141471
http://dx.doi.org/10.1097/HS9.0000000000000680
work_keys_str_mv AT bommiercome whatprognosticmarkersshouldbeevaluatedinmarginalzonelymphomaasurveyamongleadinginternationalexperts
AT lambertjerome whatprognosticmarkersshouldbeevaluatedinmarginalzonelymphomaasurveyamongleadinginternationalexperts
AT nowakowskigrzegorz whatprognosticmarkersshouldbeevaluatedinmarginalzonelymphomaasurveyamongleadinginternationalexperts
AT zuccaemanuele whatprognosticmarkersshouldbeevaluatedinmarginalzonelymphomaasurveyamongleadinginternationalexperts
AT thieblemontcatherine whatprognosticmarkersshouldbeevaluatedinmarginalzonelymphomaasurveyamongleadinginternationalexperts

Ejemplares similares